Rationale: Obstructive sleep apnea (OSA) has multiple pathophysiological causes. A low respiratory arousal threshold (ArTh) and a high loop gain (unstable ventilatory control) can contribute to recurrent respiratory events in patients with OSA. Prior small studies have shown that donepezil, an acetylcholinesterase inhibitor, might improve OSA, but the mechanism is unknown.
Obstructive sleep apnea (OSA), which is characterized by repetitive narrowing or collapse of the upper airway during sleep, is an increasing public health issue 1 . Continuous positive airway pressure is the first line treatment for OSA, but it only has an adherence rate of about 50-75% 2 .
Thus, alternative therapies targeting OSA pathogenesis are needed.
A low respiratory arousal threshold (awakening easily to respiratory stimuli) and a high loop gain (exaggerated response to ventilatory perturbations) are important non-anatomical contributors in a substantial proportion of patients with OSA 3 . Respiratory events terminated with cortical arousals are associated with increased risk of secondary respiratory events compared to events without arousals 4 . Moreover, premature arousals may disrupt accumulation of respiratory stimuli, which could activate upper airway dilator muscles and help achieve stable breathing 6 . A high loop gain, which is associated with enhanced ventilation responses and sequential excessive blood gas fluctuations, may lead to instability of ventilation during sleep, resulting in an increase in respiratory events 5 . Therefore, pharmacologically increasing arousal threshold (ArTh) and/or decreasing loop gain may be beneficial for some OSA patients [7] [8] [9] . Some sedative medications have been reported to increase the ArTh and eliminate sleep apnea in patients with low ArTh [7] [8] [9] ; decreasing loop gain by medication or supplemental oxygen might improve sleep apnea severity 10, 11 .
Donepezil is a reversible acetylcholinesterase inhibitor commonly used to treat
Alzheimer's disease (AD). Prior small studies have shown that donepezil improved OSA in both patients with and without AD over a period of weeks 12, 13 . Acetylcholine plays an important role in the sleep process and modulation of ventilatory control [14] [15] [16] . Moreover, we have previously identified an important medullary region with heavy cholinergic staining which we believe is crucial for pharyngeal patency 17, 18 . Thus, pharmacological manipulation of acetylcholine might improve sleep apnea via augmenting pharyngeal protective reflexes. However, the mechanism of potential improvement in OSA with donepezil is unknown. The hypothesis of this study is that a single dose of donepezil 10mg will reduce the apnea hypopnea index (AHI) by modulating the ArTh.
Methods

Study Design
A double-blind randomized crossover study design was used. All participants underwent two in-lab overnight polysomnograms (PSGs) at least 12 days apart based on the pharmacological half-life of donepezil (t1/2 = 70 hours). Subjects were administered either 10 mg of donepezil or an indistinguishable placebo (in blinded, arbitrary order) two hours before sleep. When they returned for a second PSG, they received a placebo or donepezil 10 mg based on initial randomization.
Power Calculation
The number of observations needed was estimated according to the values of the standard deviation of the difference in apnea-hypopnea index (AHI) seen in a prior study of donepezil 12 .
With a 90% power to reject the null hypothesis and alpha = 0.05,the estimated sample size was 38 subjects. Based on a 10% dropout rate we recruited 44 subjects.
Participants
Patients were eligible for the study if they were 18-70 years of age. All subjects had a history of untreated OSA with an AHI greater than 5 events/h according to American Academy of Sleep Medicine Task Force criteria 14 . Exclusion criteria were presence of pulmonary, cardiac, neurological or other active severe medical or psychiatric diseases; current use of continuous positive airway pressure therapy. No drugs that might interact with the investigational medication or known to affect sleep were taken during the trial or one month before the study.
We also excluded patients with known allergy to donepezil, currently smoking, or taking alcohol>3 oz per day. Written informed consent was signed by the subject before participation in the study, and the study protocol was approved by the Human Research Committee, University of California San Diego.
Polysomnography
Electroencephalograms, electrooculograms, and surface electromyograms were applied to score arousals, leg movements, and sleep stage. Abdominal and chest movements, pulse oxygen saturation, oral and nasal flow were recorded to detect respiratory events. Participants were instructed to sleep supine as much as possible throughout the duration of the night. PSGs were analyzed by experienced technicians who were blinded to both the order of medication/placebo and the ArTh measurement according to the scoring guidelines of American Academy of Sleep Medicine Task Force criteria 19 .
Arousal Threshold Measurements
Respiratory ArTh was measured using previously reported methods [7] [8] [9] 20 . Briefly, subjects were instrumented overnight with an epiglottic pressure catheter (model MCP-500; Millar, Houston, TX). ArTh was defined as the average nadir epiglottic pressure immediately prior to cortical arousal (>3 sec of high-frequency activity on the EEG) from 20 randomly selected respiratory events. To evaluate the impact of epiglottic pressure monitoring on the assessment of the change of sleep parameters with donepezil, ArTh was assessed in 21 of the 41 subjects (i.e.
about the half the subjects slept without a catheter in place).
Loop Gain Analyses
The sensitivity of the ventilatory control system (loop gain) was quantified by fitting a simplified mathematical model to the spontaneous ventilatory pattern of OSA 21 . Loop gain is reflected in the size of the ventilatory overshoot following a ventilatory perturbation (hypopnea/apnea), where loop gain = response/disturbance. Ventilatory fluctuations are estimated using the square-root transformed nasal pressure waveform. Loop gain was reported as the ventilatory response to a 1 cycle/min disturbance (LG1); a value of LGn>1 yields periodic central apnea.
Calculations were performed using MATLAB (MathWorks, Natick, MA, USA).
Statistical Analysis
Statistical analyses were performed using SPSS 22.0 (SPSS Inc., Chicago, Illinois). Sleep parameters with placebo or donepezil were compared using the Wilcoxon signed ranks test.
Obstructive sleep apnea severity and loop gain with placebo or donepezil were compared using t test. The respiratory arousal thresholds with placebo and donepezil were compared using
Mann-Whitney U test. Spearman's correlation coefficient was used to identify significant associations. Statistical significance was set at p < 0.05.
Results
Of the 44 subjects recruited, one quit the study because of difficulty in falling asleep in the lab after taking placebo; one reported "heartburn" and decided to quit after taking placebo; one was excluded due to a pulmonary embolism detected 10 days after placebo administration and prior to the second study night. The final sample consisted of the remaining 41 patients. One subject reported mild nausea after completing the study, however, no unanticipated problems related to donepezil were observed during the study.
The characteristics of the participants are listed in Table 1 . BMI did not change between placebo visit to donepezil visit (p=0.349). There were no significant statistical differences in anthropometric or the baseline sleep apnea severity in the patients with or without epiglottic pressure assessment (p > 0.05, see supplementary material for details).
Effect of Donepezil on Obstructive Sleep Apnea Severity and Sleep Parameters
Sleep apnea severity was not different between donepezil and placebo ( In 25 (61.0%) of the study population, the AHI difference between the two nights of the recording was greater than 5 events/hr. Reduction in AHI ≥10% and ≥15% with donepezil were observed in 15 (36.6%) and 9 (22.0%) patients; increase of AHI ≥10% and ≥15% with donepezil were found in 9 (22.0%) and 6 (14.6%) subjects.
There were two people who had substantially increased AHI (>30 events/h) with donepezil compared with placebo condition (Subject 2, AHI=85 events/h at baseline and 117.2 events/h with donepezil; Subject 41, AHI=79.8 events/h at baseline and 115.1 events/h with donepezil). If we remove these two outliers, we do see a significant improvement in AHI in the remaining participants, but we view such analyses as exploratory and require further study. (Table 3) . Figure 2 .
Effect of Donepezil on Respiratory Arousal Threshold
Effect of Donepezil on Loop Gain
As a whole group, loop gain at a disturbance of frequency 1 cycle /minute (LG1) did not change significantly with placebo and donepezil (0.58±0.16 vs 0.55±0.15, t=1.744, p=0.089). In the subject with a relatively high LG1 (LG1>0.5, n=26), LG1 were slightly lower with donepezil (0.67±0.13 vs 0.62±0.14, t=2.093, p=0.046). Figure 3 shows individual LG1 change with placebo and donepezil in subjects.
The Relationships between the Changes in Physiological Traits and the Treatment Responses
Given the wide range of responses in OSA severity to donepezil and the underlying physiological traits, we sought to understand the relationship between changes in AHI and the underlying traits. In the 21 patients with epiglottic pressure measurement, there was no significant association between the changes of AHI and the change of ArTh (r=0.331, P=0.143, Figure 4 ). There was a positive association between the changes of AHI and the changes of LG1 (r=0.325, p=0.038, Figure 5 ).
Discussion
We identify 3 major findings of this study. First, we did not find a consistent change in sleep apnea severity with a single dose of 10mg donepezil. Moreover, some individuals with severe OSA even showed significant increases in AHI with donepezil raising potential safety concerns.
Second, donepezil may be associated with decreased sleep efficiency compared with placebo.
Third, there were no significant changes in respiratory ArTh and loop gain for the donepezil vs.
placebo night. However, loop gain might decrease with donepezil in the select subjects with relatively high loop gains.
To our knowledge, no previous studies have examined the acute effect of donepezil on OSA. To date, there are two studies supporting the beneficial impact of donepezil on AHI, nadir oxygen saturation as well as Epworth Sleepiness Scale (ESS) score in patients with or without dementia 12 13 . The major findings of the present study are different from the previous one 12 , who observed improvement in OSA severity from 42.2 events/hour to 32.8 events/hour with 2-4 weeks of daily donepezil. There are several potential reasons for the inconsistency across studies. First, in one prior study, donepezil was given at a dosage of 5 mg /day for the first two weeks and 10 mg/day for the last two weeks for non-dementia OSA patients. Given the medication may have some beneficial effects on the long-term facilitation of upper airway dilatory muscle activity and ventilatory control, a single night of therapy may be insufficient to see potential benefits.
Moreover, donepezil inhibits acetylcholinesterase dose-dependently in the human brain in vitro 22 . Because donepezil has a long elimination half-time of ~70 hours 23 , longer duration of medication administration might generate a more robust effect.
In addition, the current study population covered a larger range of baseline AHI (with a range of 6.1-101.3 events/h) compared to the previous studies. None of the previous studies included subjects with a baseline AHI >70 events/h while eleven were included in our study.
Among these subjects, two had substantially increased AHI (>30 events/h) with donepezil compared with placebo condition (Subject 2, AHI=85 events/h at baseline and 117.2 events/h with donepezil; Subject 41, AHI=79.8 events/h at baseline and 115.1 events/h with donepezil).
In contrast, no increase of over 15 events/h or more in AHI under donepezil condition was observed in the prior studies.
Interestingly, if the two outliers who experienced deterioration are removed, we do see a small but significant improvement in AHI in the remaining participants, but we recognize such subgroup analyses are underpowered and therefore exploratory. Thus, the discrepancy of the results between various studies might be due to subject characteristics as well. Moreover, physiological characteristics could be used in subsequent studies to determine who may be good candidates for pharmacological intervention. To our knowledge, no previous study examining the effect of donepezil on arousal threshold or loop gain in patients with OSA has been reported. We found no change in either arousal threshold or loop gain with acute administration of donepezil.
Breathing control is relatively stable in slow wave sleep, and the upper airway is considered to be more vulnerable to collapse during REM 24, 25 . Thus, change in sleep architecture may also be related to the severity of sleep apnea. Our results were consistent with one previous study showing decreases in REM latency and increases in REM percentage in the first donepezil night in healthy persons 26 . Although REM sleep percentage increased from 13.5% to 15% with donepezil, REM AHI and NREM AHI were not changed by donepezil.
Furthermore, slow wave sleep percentage was not changed by donepezil 27, 28 . Therefore, it is unlikely that acute donepezil has a major impact on AHI through sleep stage migration.
One consideration when we designed the experiment was the impact of epiglottic pressure monitoring on the assessment of sleep parameters. In an early report, there was a statistically insignificant trend for reduced sleep quality and oxygen saturation with esophageal pressure monitoring 29 . A more recent study reported that an epiglottic catheter was well tolerated and also found no statistically significant impact on sleep quality parameters or sleep apnea severity 30 . In the present study, the changes of sleep apnea severity or sleep architecture with donepezil were not significantly different in the group with epiglottic pressure catheter from the group without catheter (see supplement results).
A different order of donepezil and placebo administration may alter the effects of donepezil by the "first night effect" 31 , which refers to lower sleep efficiency and less REM sleep during the first in-lab polysomnographic study in a series of polysomnograms. In theory, this effect should be minimized by a randomized study design. With further analyses, we also confirmed no significant impact of order of medication vs placebo administration in our study (see supplement results).
Limitations
We performed an acute experimental study and thus we did not test the long-term effect of donepezil on OSA severity and the physiological traits.
Considering the severity of OSA decreased about 25% with long-term donepezil administration in prior studies 12 , one could consider pharmacological treatment of OSA as a short term alternative i.e. applied when patients are short term off CPAP. In theory, a subset of patients with particular physiological features may respond well to the medication. Our study results did not show an improvement of OSA severity with a single dose of donepezil. Thus it is unlikely that donepezil could be used as a short-term alternative treatment for OSA patients.
We call for more research to determine the short term and long term effects of various potential pharmacotherapies in OSA.
The one sleep apnea phenotypic trait we did not measure was upper airway muscle effectiveness (so called upper airway gain). Cholinergically mediated neurons have been reported to promote upper airway negative pressure reflexes in animal studies 17 . Thus, we would advocate for future studies to assess the impact of donepezil on upper airway motor control and perhaps to identify patients likely to respond to donepezil by measuring upper airway mechanics.
Summary
Overall, in contrast with the beneficial effect of longer administration of donepezil in patients with OSA previously reported, a single dose of 10mg donepezil does not appear to affect the severity of OSA, and no consistent effects on arousal threshold were observed. As some individuals with severe OSA showed significant increases in AHI with donepezil, the potential risk of donepezil in worsening sleep apnea should be considered in certain patients. In addition, the underlying mechanism(s) of sleep apnea is likely to vary across individuals such that one might predict that an intervention may only be effective in a subset of OSA patients. However, whether there is a readily identifiable subset of OSA patients who may respond well to donepezil remains unclear. Change in AHI during the placebo/donepezil condition and the change of the respiratory arousal threshold. There was no significant association between the changes of AHI and the change of ArTh (r=0.331, P=0.143). figure 4 60x48mm (300 x 300 DPI) Change in AHI during the placebo/donepezil condition and the change of loop gain (the ventilatory response to a 1 cycle/min disturbance,LG1) There was a positive association between the changes of AHI and the changes of LG1 (r=0.325, p=0.038). figure 5 60x48mm (300 x 300 DPI)
SUPPLEMENT RESULTS
The impact of epiglottic pressure measurements on the assessment of sleep parameters
Forty-one subjects completed the study. There were no statistically significant differences in mean age, baseline AHI, nadir oxygen desaturation during (LSAT) or the BMI in the patients with or without epiglottic pressure assessment for arousal threshold (Table S1) The changes of sleep apnea severity or sleep architecture with donepezil were not significantly different in the group with epiglottic pressure catheter from the group without catheter (Table   S2 ).
The impact of the order of donepezil and placebo administration on the study results
The impact of order of medication vs placebo administration on sleep parameters and sleep apnea severity was assessed by comparing the changes of sleep and physiological traits in patients with different medication/placebo administration orders (Table S3) . No difference was found between the patients with different medication/placebo administration orders. Abbreviations: NREM, Non rapid eye movement sleep; AHI, apnea hypopnea index; LSAT, Nadir oxygen saturation during sleep. (Normally distributed data were showed as mean ± Std. deviation) , LG1, Loop gain (at a disturbance of frequency 1 cycle /minute).* p<0.05
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